NUCLIDIUM today announced that the first patient has been successfully imaged in a phase 1 clinical trial evaluating the company's radiotracer candidate as a safe and accurate diagnostic and ...
Base Molecular Resonancetm Technologies (BMRT) announces a $1.8 billion valuation for its IP licensing in the U.S. security market, issued by IP Capital Group (ipCG), a renowned IP firm founded by ...